Prescient (ASX: PTX) makes ‘solid progress on all fronts’ in June quarter
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key...
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing...
Prescient Therapeutics (ASX: PTX) signed off the March quarter with major progress made in its Cell...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment...
Cancer results from the mutation of normal cells to tumour cells because of interaction between...
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
Cancer is one of the significant causes of death worldwide. As per the World Health...
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.